About Viking Therapeutics, Inc. - Common Stock (VKTX)
Viking Therapeutics is a biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders. The company is engaged in advancing a portfolio of drug candidates aimed at addressing diseases with significant unmet medical needs, including non-alcoholic steatohepatitis (NASH) and obesity. Viking’s approach leverages proprietary drug development technologies to design and optimize novel therapeutic compounds, with an emphasis on safety and efficacy. Through its research and clinical trials, the company aims to bring transformative treatments to market that can improve patient outcomes and enhance quality of life. Read More
Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table?
The obesity treatment market is exploding, with Goldman Sachs projecting it to reach $130 billion by 2030. Driven by rising global obesity rates—now at 42% of U.S. adults, per the CDC—the sector has become a magnet for investors seeking exposure to transformative medicine.
